The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Open accessAbstract
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors. Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation. Genetic or pharmacological inhibition of AXL restored sensitivity to erlotinib in these tumor models. Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs. These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhibition of the FGFR signaling pathway reduces ERK and mTOR activation, whereas AXL inhibition attenuates the activation of PI3K pathway [43, 136–139].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [43]
In the citing paper
“High feedback activation of the FGFR/AXL signaling pathway was found in mesenchymal cells.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [43]
In the citing paper
“In the context of an EMT, AXL upregulation appears as a novel mechanism of acquired EGFR-TKI resistance in EGFR-mutant NSCLCs.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“Therefore, an EMT-associated transcriptional programme involving upregulation of vimentin may, in part, drive AXL overexpression in EGFR-mutant lung cancer cells with acquired EGFR-TKI resistance.40”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“Pharmacological inhibition of AXL significantly decreased the proliferative and invasive abilities of cancer cells and increased their chemosenstivity through inhibition of AKT and MAPK pathways.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“Rare EGFR point mutations (<10% of patients) that result in resistance include Asp761Tyr,39 Thr854Ala,40 and Leu747Ser. The mechanism (or mechanisms) underlying resistance conferred by these mutations is still unclear.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“Recently, an integrated analysis in human EGFR-mutant NSCLC models and in a large clinical cohorts of paired NSCLC specimens from EGFR-TKI-treated patients demonstrated an upregulation of AXL tyrosine kinase receptor or of its ligand, GAS6, in resistant samples.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“We observed an AXL mutation in one case with acquired T790M/C797S (Pt. 12 Supple Table 2)[24], suggesting association with EMT.”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [24]
In the citing paper
“AXL inhibition has been reported to sensitize drug-resistant mesenchymal tumor cells to anticancer agents, including antimitotic agents, epidermal growth factor receptor (EGFR) inhibitors, and PI3K inhibitors”
From Hypoxic control of metastasis (2016) · cites this paper as [84]
In the citing paper
“Finally, in erlotinib-resistant EGFR mutant lung cancer cells and lapatinib-resistant HER2-amplified breast cancer cells, levels of the AXL RTK were markedly increased (Liu et al., 2009; Zhang et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Zhang et al., 2012
In the citing paper
“Targeting AXL was able to re-sensitize some of these resistant cancers to the original TKI.”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Zhang et al., 2012
In the citing paper
“In similar examples of resistance mediated by IGF-IR and AXL, inhibition of the bypass RTK in combination with the EGFR is needed to overcome resistance (Cortot et al., 2013; Guix et al., 2008; Zhang et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Zhang et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,000
Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death
Song, K.-A., & Faber, A. C. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.11 · Cited by 38
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 40
Jung, C. Y., Kim, S., & Lee, C. (2018) · Anticancer Research · doi:10.21873/anticanres.12219 · Cited by 38
Self-citationIdentification, functional insights and therapeutic targeting of EMT tumour states
Dong, A., & Blanpain, C. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00873-0 · Cited by 41
Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer
Haghgoo, S. M., Allameh, A., Mortaz, E., Garssen, J., Folkerts, G., Barnes, P. J., & Adcock, I. M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.029 · Cited by 39
Sereno, M., Moreno, V., Moreno‐Rubio, J., Gómez-Raposo, C., Sánchez, S. G., Jusdado, R. H., Falagán, S., Tévar, F. Z., & Sáenz, E. C. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000277 · Cited by 37
Brown, M., Black, J. R., Sharma, R., Stebbing, J., & Pinato, D. J. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203629 · Cited by 37
Chia, S., Ellard, S. L., Mates, M., Welch, S. A., Mihalcioiu, C. L. D., Miller, W. H., Gelmon, K. A., Lohrisch, C. A., Kumar, V., Taylor, S., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0836-3 · Cited by 38
Oien, D. B., Garay, T., Eckstein, S., & CHIEN, J. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00970 · Cited by 37
AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells
Zajac, O., Leclère, R., Nicolas, A., Meseure, D., Marchiò, C., Vincent‐Salomon, A., Roman‐Roman, S., Schoumacher, M., & Dubois, T. (2020) · Cells · doi:10.3390/cells9010247 · Cited by 37
Guo, S., Zhang, J., Wei, C., Lü, Z.-Y., Cai, R., Pan, D., Zhang, H., Liang, B., & Zhang, Z. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04083-3 · Cited by 37
Self-citationCell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 41
Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future
Cagle, P. T., & Allen, T. C. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0508-ra · Cited by 36
Nurwidya, F., Takahashi, F., Murakami, A., Kobayashi, I., Kato, M., Shukuya, T., Tajima, K., Shimada, N., & Takahashi, K. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.07.007 · Cited by 37
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
Cirone, P., Andresen, C. J., Eswaraka, J. R., Lappin, P. B., & Bagi, C. M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2376-1 · Cited by 37
FBW7 Upregulation Enhances Cisplatin Cytotoxicity in Non-small Cell Lung Cancer Cells
Yu, H., Wei, W., Xia, L.-H., Han, W., Zhao, P., Wu, S., Li, W., & Chen, W. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.11.6321 · Cited by 36
Gower, A., Hsu, W., Hsu, S.-T., Wang, Y., & Giaccone, G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.007 · Cited by 37
ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL
Wang, Y., Guan, G., Cheng, W., Jiang, Y., Shan, F., Wu, A., Cheng, P., & Guo, Z. (2018) · BMC Cancer · doi:10.1186/s12885-018-4517-0 · Cited by 36
Stromal Gas6 promotes the progression of premalignant mammary cells
Gomes, A. M., Carron, E. C., Mills, K. L., Dow, A. M., Gray, Z., Fecca, C. R., Lakey, M. A., Carmeliet, P., Kittrell, F. S., Medina, D., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0593-5 · Cited by 36
Jönsson, V. D., Blakely, C. M., Lin, L., Asthana, S., Matni, N., Olivas, V. R., Pazarentzos, E., Gubens, M. A., Bastian, B. C., Taylor, B. S., et al. (2017) · Scientific Reports · doi:10.1038/srep44206 · Cited by 36
Self-citationCell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands
Hassanein, S. S., Ibrahim, S., & Abdel-Mawgood, A. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212496 · Cited by 36
Tang, Q., Wang, L., Duan, Y., Wang, W., Huang, S., Zhi, J., Jia, S., Zhu, W., Wang, P., Luo, R., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.045 · Cited by 36
Corte, C. M. D., Ciaramella, V., Cardone, C., Monica, S. L., Alfieri, R. R., Petronini, P. G., Malapelle, U., Vigliar, E., Pepe, F., Troncone, G., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.025 · Cited by 36
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
Antony, J., Zanini, E., Kelly, Z., Tan, T. Z., Karali, E., Alomary, M. N., Jung, Y., Nixon, K., Cunnea, P., Fotopoulou, C., et al. (2018) · EMBO Reports · doi:10.15252/embr.201745670 · Cited by 36
Yang, L., Lee, R. K., Kuo, M.-H., Miao, C., Wang, Y., Chen, A., Jhu, Y., Cheng, H.-I., Pan, S., & Chou, Y. (2022) · International Journal of Cancer · doi:10.1002/ijc.34193 · Cited by 35
Sunitinib activates Axl signaling in renal cell cancer
van der Mijn, J. C., Broxterman, H. J., Knol, J. C., Piersma, S. R., de Haas, R. R., Dekker, H., Pham, T. V., van Beusechem, V. W., Halmos, B., Mier, J. W., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30022 · Cited by 37
Self-citationZhang, J., Chang, L., Jin, H., Xia, Y., Wang, L., He, W., Li, W., & Chen, H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216644530 · Cited by 35
Ni, Y., Bi, J., Ye, X., Fan, W., Yu, G., Yang, X., Huang, G., Li, W., Wang, J., Han, X., et al. (2016) · Medicine · doi:10.1097/md.0000000000003998 · Cited by 35
Li, L., Gu, X., Yue, J., Zhao, Q., Lv, D., Chen, H., & Xu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.21170 · Cited by 36
The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review
Zhang, S., Xu, X. S., Yang, J. X., Guo, J., Chao, T. F., & Tong, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s150952 · Cited by 35
Nan, X., Li, H., Fang, S., Li, Q., & Wu, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112241 · Cited by 35
Wang, F., Meng, F., Wong, S. C. C., Cho, W. C. S., Yang, S., & Chan, L. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620915156 · Cited by 35
Yoshimura, A., Yamada, T., Okuma, Y., Fukuda, A., Watanabe, S., Nishioka, N., Takeda, T., Chihara, Y., Takemoto, S., Harada, T., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-461 · Cited by 35
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Yan, D., Earp, H. S., DeRyckere, D., & Graham, D. K. (2021) · Cancers · doi:10.3390/cancers13225639 · Cited by 35
Torka, R., Pénzes, K., Gusenbauer, S., Baumann, C., Szabadkai, I., Őrfi, L., Kéri, G., & Ullrich, A. (2014) · Neoplasia · doi:10.1016/j.neo.2014.03.009 · Cited by 35
Kong, S. L., Li, H., Tai, J. A., Courtois, E. T., Poh, H. M., Lau, D. P., Haw, Y. X., Iyer, N. G., Tan, D. S. W., Prabhakar, S., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.295717 · Cited by 37
Antibody–drug conjugates for lung cancer in the era of personalized oncology
Ricciuti, B., Lamberti, G., Andrini, E., Genova, C., Giglio, A. D., Bianconi, V., Sahebkar, A., Chiari, R., & Pirro, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.024 · Cited by 35
Kanda, S., Horinouchi, H., Fujiwara, Y., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Kubota, K., Tamura, T., & Ohe, Y. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.016 · Cited by 34
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34
Self-citationCodony‐Servat, J., García-Román, S., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Giménez-Capitán, A. A., Viteri, S., Cardona, A. F., d'Hondt, E., Karachaliou, N., & Rosell, R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.030 · Cited by 34
Self-citationNokihara, H., Nishio, M., Yamamoto, N., Fujiwara, Y., Horinouchi, H., Kanda, S., Horiike, A., Ohyanagi, F., Yanagitani, N., Nguyen, L. T., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.018 · Cited by 34
AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer
Engelsen, A. S. T., Wnuk-Lipińska, K., Bougnaud, S., Vatter, F. A. P., Tiron, C. E., Villadsen, R., Miyano, M., Lotsberg, M. L., Madeleine, N., Panahandeh, P., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101649 · Cited by 34
AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer
Du, W., Phinney, N. Z., Huang, H., Wang, Z., Westcott, J. M., Toombs, J. E., Zhang, Y., Beg, M. S., Wilkie, T. M., Lorens, J. B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0860 · Cited by 36
Mizumoto, A., Yamamoto, K., Nakayama, Y., Takara, K., Nakagawa, T., Hirano, T., & Hirai, M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226639 · Cited by 34
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas
May, C. D., Garnett, J., Ma, X., Landers, S. M., Ingram, D. R., Demicco, E. G., Sannaa, G. A. A., Vu, T., Han, L., Zhang, Y., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1916-3 · Cited by 34
Yu, Y., Abudula, M., Li, C., Chen, Z., Zhang, Y., & Chen, Y. (2019) · Respiratory Research · doi:10.1186/s12931-019-1202-z · Cited by 33
Liu, D., Che, X., & Wu, G. (2024) · Biomarker Research · doi:10.1186/s40364-023-00545-x · Cited by 34
Cruz, M. C. P. D., & Medina, P. M. B. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.001 · Cited by 34
mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF
Ishikawa, D., Takeuchi, S., Nakagawa, T., Sano, T., Nakade, J., Nanjo, S., Yamada, T., Ebi, H., Zhao, L., Yasumoto, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062104 · Cited by 33
Ono, N., Yamazaki, T., Tsukaguchi, T., Fujii, T., Sakata, K., Suda, A., Tsukuda, T., Mio, T., Ishii, N., Kondoh, O., et al. (2013) · Cancer Science · doi:10.1111/cas.12237 · Cited by 34
Suda, K., Bunn, P. A., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.003 · Cited by 33
Palisoul, M. L., Quinn, J. M., Schepers, E. J., Hagemann, I. S., Guo, L., Reger, K., Hagemann, A. R., McCourt, C. K., Thaker, P. H., Powell, M. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0587 · Cited by 33
Shaik, N. A., Alkreathy, H. M., Ajabnoor, G., Verma, P. K., & Banaganapalli, B. (2018) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2018.05.026 · Cited by 33
Li, F., Zhu, T., Yue, Y., Zhu, X., Wang, J., & Liang, L. (2018) · Oncology Reports · doi:10.3892/or.2018.6474 · Cited by 33
Yao, Y., Yang, H., Zhu, B., Wang, S., Pang, J., Wu, X., Xu, Y., Zhang, J., Zhang, J., Ou, Q., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02329-1 · Cited by 33
Wang, X., Li, G., Koul, S., Ohki, R., Maurer, M., Borczuk, A., & Halmos, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3674 · Cited by 34
Self-citationAXL and acquired resistance to EGFR inhibitors
Postel-Vinay, S. C., & Ashworth, A. (2012) · Nature Genetics · doi:10.1038/ng.2362 · Cited by 33
Negrao, M. V., Paula, A. G., Molkentine, D. P., Hover, L. D., Nilsson, M. B., Vokes, N. I., Engstrom, L. D., Calinisan, A., Briere, D. M., Waters, L. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2310 · Cited by 33
Paccez, J. D., Duncan, K., Vava, A., Correa, R. G., Libermann, T. A., Parker, M. I., & Zerbini, L. F. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0868 · Cited by 32
Tang, Q., Zhang, G., Du, X., Zhu, W., Li, R., Lin, H., Li, P., Cheng, M., Gong, P., & Zhao, Y. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.01.014 · Cited by 32
Yamaoka, T., Ohmori, T., Ohba, M., Arata, S., Kishino, Y., Murata, Y., Kusumoto, S., Ishida, H., Shirai, T., Hirose, T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0313 · Cited by 32
Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma
Hossain, J. A., Latif, A., Ystaas, L., Ninzima, S., Riecken, K., Muller, A., Azuaje, F. J., Joseph, J. V., Talasila, K. M., Ghimire, J., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz060 · Cited by 32
Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer
Shankaraiah, N., Nekkanti, S., Ommi, O., & Soukya, P. S. L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180410110729 · Cited by 32
Divine, L. M., Nguyen, M. R., Meller, E. H., Desai, R. A., Arif, B., Rankin, E. B., Bligard, K. H., Meyerson, C., Hagemann, I. S., Massad, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12637 · Cited by 32
Fujino, N., Kubo, H., & Maciewicz, R. A. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.52 · Cited by 32
Yan, S., Vandewalle, N., Beule, N. D., Faict, S., Maes, K., Bruyne, E. D., Menu, E., Vanderkerken, K., & Veirman, K. D. (2019) · Cancers · doi:10.3390/cancers11111727 · Cited by 32
Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation
Kim, D. H., Kim, H. C., Im, K., Baek, I.-J., Choi, Y. J., Lee, H., Kim, D.-S., Lee, C. W., Jeong, J., Ban, K., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.00615-2024 · Cited by 32
Self-citationAXL: shapers of tumor progression and immunosuppressive microenvironments
Liu, Y., Xu, L., Dou, Y., & He, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02210-9 · Cited by 38
Kim, G. W., Song, J. S., Choi, C., Rho, J. K., Kim, S. Y., Jang, S. J., Park, Y. S., Chun, S., Kim, W. S., Lee, J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.023 · Cited by 31
Self-citationOptimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer
Meador, C. B., Jin, H., de Stanchina, E., Nebhan, C. A., Pirazzoli, V., Wang, L., Wang, L., Vuong, H., Hutchinson, K. E., Jia, P., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0723 · Cited by 31
Self-citationChung, C. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215577810 · Cited by 31
Update in Lung Cancer and Mesothelioma 2012
Powell, C. A., Halmos, B., & Nana-Sinkam, S. P. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0716up · Cited by 32
Self-citationMizuuchi, H., Suda, K., Murakami, I., Sakai, K., Sato, K., Kobayashi, Y., Shimoji, M., Chiba, M., Sesumi, Y., Tomizawa, K., et al. (2016) · Cancer Science · doi:10.1111/cas.12905 · Cited by 31
Hu, S., Dai, H., Li, T. X., Tang, Y., Fu, W., Yuan, Q., Wang, F., Lv, G., Lv, Y., Fan, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.022 · Cited by 31
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Galvani, E., Sun, J., León, L. G., Sciarrillo, R., Narayan, R. S., Sjin, R. T. T., Lee, K., Ohashi, K., Heideman, D. A. M., Alfieri, R. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3956 · Cited by 32
Jang, J.-Y., Kim, Y.-G., Nam, S. J., Keam, B., Kim, T. M., Jeon, Y. K., & Kim, C. W. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0089 · Cited by 31
Emdal, K. B., Dittmann, A., Reddy, R. J., Lescarbeau, R. S., Moores, S. L., Laquerre, S. G., & White, F. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0413 · Cited by 33
Does Axl have potential as a therapeutic target in pancreatic cancer?
Du, W., & Brekken, R. A. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1527315 · Cited by 32
Pathak, R., & Villaflor, V. M. (2021) · Cancers · doi:10.3390/cancers13184641 · Cited by 30
Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
Wu, D., Sun, Q., Tang, H., Xiao, H., Luo, J., Ouyang, L., & Sun, Q. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101176 · Cited by 32
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00112 · Cited by 31
Murakami, Y., Sonoda, K., Abe, H., Watari, K., Kusakabe, D., Azuma, K., Kawahara, A., Akiba, J., Oneyama, C., Pachter, J. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19982 · Cited by 30
Calder, J., Nagelberg, A. L., Luu, J., Lu, D., & Lockwood, W. W. (2021) · Oncogenesis · doi:10.1038/s41389-021-00316-z · Cited by 32
Quan, C., Chen, Y., Wang, X., Yang, D. L., Wang, Q., Huang, Y., Petersen, R. B., Liu, X., Zheng, L., Li, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.003 · Cited by 30
Self-citationGene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer
Hijazo‐Pechero, S., Alay, A., Marín, R., Vilariño, N., Muñoz‐Pinedo, C., Villanueva, A., Santamarı́a, D., Nadal, E., & Solé, X. (2021) · Cancers · doi:10.3390/cancers13194734 · Cited by 30
Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects
Rettew, A. N., Getty, P. J., & Greenfield, E. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_3 · Cited by 30
Du, Y., Zhang, Q., Jing, L., Liang, X., Chi, C., Li, Y., Yang, X., Dai, Z., & Tian, J. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s82029 · Cited by 30
AKT inactivation causes persistent drug tolerance to EGFR inhibitors
Tetsu, O., Phuchareon, J., Eisele, D. W., Hangauer, M. J., & McCormick, F. P. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.022 · Cited by 31
Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor
Forest, A., Amatulli, M., Ludwig, D. L., Damoci, C. B., Wang, Y., Burns, C. A., Donoho, G. P., Zanella, N., Fiebig, H., Prewett, M. C., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0279 · Cited by 31
Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas
Yao, T.-W., Zhang, J., Prados, M., Weiss, W. A., James, C. D., & Nicolaides, T. P. (2016) · Oncotarget · doi:10.18632/oncotarget.11882 · Cited by 30
Kleczko, E. K., & Heasley, L. E. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0816-y · Cited by 31
Suresh, D., Zambre, A. P., Mukherjee, S., Ghoshdastidar, S., Jiang, Y., Joshi, T., Upendran, A., & Kannan, R. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.04.010 · Cited by 30
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Hu, B., Wiesehöfer, M., de Miguel, F. J., Liu, Z. Z., Chan, L.-H., Choi, J., Melnick, M. A., Estape, A. A., Walther, Z., Zhao, D., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-0438 · Cited by 29
MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer
Donzelli, S., Cioce, M., Muti, P. C., Strano, S., Yarden, Y., & Blandino, G. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.12.020 · Cited by 29
Kimani, S. G., Kumar, S., Davra, V., Chang, Y., Kasikara, C., Geng, K., Tsou, W., Wang, S., Hoque, M., Boháč, A., et al. (2016) · Cell Communication and Signaling · doi:10.1186/s12964-016-0142-1 · Cited by 30
At the crossroads of cancer stem cells and targeted therapy resistance
Wang, A., Qu, L., & Wang, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.039 · Cited by 31
HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss
Shin, C., Robinson, J. P., Sonnen, J. A., Welker, A., Yu, D., VanBrocklin, M. W., & Holmen, S. L. (2017) · Oncogene · doi:10.1038/onc.2017.83 · Cited by 29
Leighl, N. B., Tsao, M., Liu, G., Tu, D., Ho, C., Shepherd, F. A., Murray, N., Goffin, J. R., Nicholas, G. A., Sakashita, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18753 · Cited by 29
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment
Zaman, A., & Bivona, T. G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.02 · Cited by 29
Self-citationTargeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080192 · Cited by 29
Metadata
- Authors
- Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., Choi, Y. J., Choi, C.-M., Kim, S.-W., Jang, S. J., Park, Y. S., Kim, W. S., Lee, D. H., Lee, J.-S., Miller, V. A., Arcila, M., Ladanyi, M., Moonsamy, P., Sawyers, C., Boggon, T. J., Ma, P. C., Costa, C., Taron, M., Rosell, R., Halmos, B., & Bivona, T. G.
- Affiliations
- Columbia University Irving Medical Center (US)
- Asan Medical Center (KR)
- University of California, San Francisco (US)
- University Hospitals Cleveland Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Cleveland Clinic (US)
- Institut Català d'Oncologia (ES)
- Corresponding author
- Bivona, Trever G
- ORCID
- Zhang, Zhenfeng
- Lee, Jae Cheol
- Lin, Luping
- LaFramboise, Thomas
- Wang, Xiaoqi
- Levine, Alan D
- Rho, Jin Kyung
- Choi, Yun Jung
- Choi, Chang-Min
- Jang, Se Jin
- Park, Young Soo
- Kim, Woo Sung
- Lee, Dae Ho
- Lee, Jung-Shin
- Miller, Vincent A
- Arcila, Maria
- Ladanyi, Marc
- Moonsamy, Philicia
- Sawyers, Charles
- Boggon, Titus J
- Rosell, Rafael
- Bivona, Trever G
- Venue
- Nature Genetics
- Published
- 2012-07-01
- Volume
- 44
- Issue
- 8
- Pages
- 852-860
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC3408577
- OpenAlex
- W1983774108
- Cited by
- 1,224
- References
- 29
- Citations by year
- 2026: 37 · 2025: 61 · 2024: 49 · 2023: 85 · 2022: 73 · 2021: 86 · 2020: 101 · 2019: 89 · 2018: 103 · 2017: 112 · 2016: 116 · 2015: 131 · 2014: 82 · 2013: 82 · 2012: 14
- FWCI
- 80.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (T35HL007616)
- National Cancer Institute (R01CA169338, DP2CA174497, P01CA129243, K08CA154787, K08 1K08CA154787)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- AXL kinase, erlotinib resistance, EGFR-mutant lung cancer, non-small cell lung cancer, tyrosine kinase inhibitors, epithelial-mesenchymal transition, Gas6, acquired drug resistance, therapeutic target, MET kinase
- MeSH terms
- Erlotinib Hydrochloride, Axl Receptor Tyrosine Kinase, Growth Arrest-Specific Protein 6, Adult, Aged, Animals, Carcinoma, Non-Small-Cell Lung, Enzyme Activation, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Quinazolines, Signal Transduction, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Receptor Protein-Tyrosine Kinases, Xenograft Model Antitumor Assays, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Protein Kinase Inhibitors, Epithelial-Mesenchymal Transition, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
